問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (在職)

Division of Pediatrics

Digestive System Department

更新時間：2023-09-19

賴明瑋Lai, Ming-Wei
  • Principal Investigator
  • Clinical Trial Experience (year) 17 years 9 個月

  • a22141@cgmh.org.tw

Recruiting Trial

8Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

賴明瑋

List

17Cases

2018-08-01 - 2023-06-26

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2018-01-01 - 2027-12-31

Phase III

A Multicenter, Randomized, Double-Blind, Placebo-Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Ulcerative Colitis

  • Condition/Disease

    Ulcerative Colitis

  • Test Drug

    Risankizumab

Participate Sites
6Sites

Recruiting5Sites

Terminated1Sites

2018-01-01 - 2020-12-31

Phase III

Efficacy and Safety of Racecadotril in the Treatment of Taiwanese Children Aged 3 to 60 Months Suffering From Acute Diarrhea: A Prospective, Open-label, Multicenter, Single-arm Study.

  • Condition/Disease

    Diarrhea, Infantile

  • Test Drug

    Hidrasec

Participate Sites
3Sites

Terminated3Sites

邱政洵
Linkou Chang Gung Medical Foundation

Division of Pediatrics

2014-05-20 - 2018-02-28

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2012-09-01 - 2017-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated2Sites

Study ended1Sites

2021-12-31 - 2024-06-30

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2018-04-01 - 2020-01-31

Phase III

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or are Intolerant to Biologic Therapy

  • Condition/Disease

    Moderately to Severely Active Crohn's Disease

  • Test Drug

    Upadacitinib (ABT-494)

Participate Sites
2Sites

Recruiting1Sites

Terminated1Sites

1 2
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB